Alnylam Pharmaceuticals Inc (ALNY) shares have surpassed the average analyst target price of $218.18, currently trading at $222.90/share. Analysts may adjust their target price based on business developments. There are 22 different analyst targets for ALNY, with a standard deviation of $55.522. Investors use the average target price to assess potential growth. Analyst ratings for ALNY include 13 Strong Buy, 3 Buy, and 9 Hold ratings. The average rating is 1.84 on a scale of 1 to 5. Data provided by Zacks Investment Research via Quandl.com.

Read more at Nasdaq: Alnylam Pharmaceuticals Reaches Analyst Target Price